Carlsmed, Inc. Overview
Pro stress-test →Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions. The company specializes in personalized spine surgical solutions, using artificial intelligence and advanced 3D surgical planning to create custom implants tailored to individual patients. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery one patient at a time.
Strategic Profile
Pro stress-test →Carlsmed delivered Q1 2026 revenue of $16.1 million, representing 58% growth year-over-year, with full year 2026 revenue guidance raised to $72-$77 million. The company achieved 86% revenue growth in 2025, driven by strong lumbar platform performance and new cervical product launches, with gross margins expanding to 75.3%. Carlsmed began trading on the Nasdaq Global Select Market under ticker CARL on July 23, 2025.
Competitive Landscape
Pro stress-test →Carlsmed competes in the personalized orthopedic implant and AI-driven surgical planning market against traditional spine device manufacturers and emerging digital surgery platforms. The company's rapid revenue growth and strong clinical validation drive adoption of its personalized spine surgery platform, now expanded to both lumbar and cervical procedures, with new reimbursement wins and technological innovations supporting continued U.S. market expansion.
Industry Context
Carlsmed, Inc. operates in Personalized orthopedic implants and AI-enabled surgical planning systems.
Key facts
Founded: 2018 · Headquarters: Carlsbad, California, US · Employees: 101-250 · Revenue: $16.1M (Q1 2026); $50.5M (FY 2025) · Market cap: N/A